CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that management will participate in the following upcoming virtual investor conferences:
Piper Sandler 32nd Annual Healthcare Conference Prerecorded fireside chat available on Monday, November 23, 2020 at 10:00 a.m. ET; Institutional investor meetings to be conducted on Tuesday, December 1, 2020
3rd Annual Evercore ISI HealthCONx Conference Fireside chat on Thursday, December 3, 2020 from 3:55 – 4:15 p.m. ET
The events will be available via webcast through the “Events & Presentations” page of the “Investors & Media” section of the company’s website at www.praxismedicines.com. Replays of the webcasts will be available for 90 days following the events.
About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. Praxis has established a broad portfolio, including five disclosed programs across multiple central nervous system disorders including, depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates.
Investor Contact: Alex Kane Praxis Precision Medicines [email protected] 617-300-8481
"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites